I guess this way they don't get randomized to placebo arm. I imagine they are getting close to stopping enrollment too. From the Goldman call (and I believe Q1 too) they said they hope to wrap up the study and have discussions with FDA on next steps by end of year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.